2. Search Result
Search Result
Results for "

HA2

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

8

Peptides

1

Inhibitory Antibodies

2

Natural
Products

1

Recombinant Proteins

2

Antibodies

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P4108
    TAT-HA2 Fusion Peptide

    		Influenza Virus Infection
    TAT-HA2 Fusion Peptide is a peptide-based delivery agent that combines the pH-sensitive HA2 fusion peptide from Influenza and the cell-penetrating peptide TAT from HIV. TAT-HA2 Fusion Peptide is a transactivator of transcription and hemaglutanin for endosomal release. TAT-HA2 Fusion Peptide enhances cellular uptake of macromolecules .
    TAT-HA2 Fusion Peptide
  • HY-P10152
    INF7

    		Biochemical Assay Reagents Infection
    INF7 is a derivative of the N-terminal domain of the HA2 protein and is sensitive to pH. INF7 disrupts the stability of endosomal membranes through a mechanism independent of membrane fusion. INF7 can be used to enhance the endosome escape of complex or liposome-encapsulated proteins. Co-encapsulation of INF7 and molecular imaging probes in liposomes can enhance intracellular signaling and probe retention [2].
    INF7
  • HY-P5307
    Peptide A5K

    INF7-A5K-TAT

    		 Biochemical Assay Reagents Others
    Peptide A5K (INF7-A5K-TAT) is an amphiphilic peptide derived from the HA2-TAT fusion scaffold. Peptide A5K can non-covalently bind to CRISPR ribonucleoproteins and efficiently deliver them to cells, such as primary human T cells, B cells, and NK cells. Peptide A5K enables low-toxicity, precise, and multiplex genome editing, holding great application potential in the field of cell therapy .
    Peptide A5K
  • HY-P99750
    Navivumab

    CT-P23

    		 Influenza Virus Infection
    Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin (HA) of influenza A virus. Navivumab binds to the HA2 stem fusion domain and the low-variability HA2 region of influenza viruses. Navivumab neutralizes influenza A viruses of subtypes H1, H2, H5, and H9. Navivumab is applicable to research related to influenza and influenza A [2] .
    Navivumab
  • HY-139314
    A2B receptor antagonist 2

    		Adenosine Receptor Metabolic Disease
    A2B receptor antagonist 2 (compound 18) is an adenosine receptor A2B antagonist, with Ki values of 2.30 μM, 6.8 μM and 3.44 μM for rA1, rA2A and hA2B, respectively .
    A2B receptor antagonist 2
  • HY-N2589
    Isosaponarin

    		TGF-β Receptor Collagen Infection Metabolic Disease Inflammation/Immunology Cancer
    Isosaponarin is a flavone glycoside isolated from wasabi leaves. Isosaponarin is a P4HA2 enzymatic agonist. Isosaponarin increases collagen synthesis via up-regulated TGF-β type II receptor (TβR-II) and prolyl 4-hydroxylase (P4H) proteins production, promoting skin health and wound healing. Isosaponarin-rich plants exhibit strong antimicrobial, antioxidant, anti-hyaluronidase, antiplatelet, anti-atopic dermatitis, and anti-tumor effects [2] .
    Isosaponarin
  • HY-N0092R
    Inosine (Standard)

    		Reference Standards Adenosine Receptor Endogenous Metabolite Neurological Disease Inflammation/Immunology
    Inosine (Standard) is the analytical standard of Inosine. This product is intended for research and analytical applications. Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A1 (A1R) and A2A (A2AR) receptors [2] . In Vitro:Inosine dose-dependently stimulates cAMP production mediated through the A2AR [2].
    Inosine dose-dependently induces hA2AR-mediated ERK1/2 phosphorylation [2].
    Inosine (100 μM; 24 hours) reduces oxidative stress in MES 23.5 cells cultured with astrocytes .
    In Vivo:Inosine (10-100 mg/kg; i.p.) exhibits antinociceptive effect in mice [2].
    Inosine (Standard)
  • HY-130178
    CL-385319

    		Endogenous Metabolite Infection
    CL-385319 is an N-substituted piperidine compound with inhibitory activity against H5N1 avian influenza A virus infection. CL-385319 exhibited an IC50 of 27.03±2.54 μM against infection of highly pathogenic H5N1 virus in Madin-Darby canine kidney cells (MDCK). CL-385319 had low cytotoxicity with a CC50 of 1.48 mM and was able to inhibit the entry of pseudoviruses carrying H5N1 strains from different sources, but had no inhibitory effect on the entry of VSV-G pseudotyped particles. Pseudoviruses with the M24A mutation in HA1 or the F110S mutation in HA2 were resistant to CL-385319, indicating that these two residues in the cavity region may be critical for the binding of CL-385319 .
    CL-385319
  • HY-P4108C
    Cys-TAT-HA2

    		Phosphodiesterase (PDE) Others
    Cys-TAT-HA2 is a conjugate of Cys and TAT-HA2 (HY-P4108). Cys-TAT-HA2 is a transduction complex that can be introduced protein (such as Cardiac troponin C) into the cytoplasm of living cells. Cys-TAT-HA2 can be used for live tracking of exogenous proteins research .
    Cys-TAT-HA2
  • HY-P11353
    HA2 peptide

    		Small Interfering RNA (siRNA) Cancer
    HA2 peptide is a potent pH-responsive fusogenic peptide derived from hemagglutinin (HA). HA2 peptide is anionic and can be conjugated to cationic peptides for siRNA condensation. HA2 peptide can be used for the research of cancer .
    HA2 peptide
  • HY-14365
    TC-G 1004

    		Adenosine Receptor Neurological Disease
    TC-G 1004 (compound 16j) is an orally active A2A adenosine receptor antagonist, with Ki values of 0.44 nM and 80 nM for hA2A and hA1, respectively .
    TC-G 1004
  • HY-P11000
    INF7TAT

    		Biochemical Assay Reagents Others
    INF7TAT is an amphipathic peptide containing the influenza HA2 sequence and the TAT peptide (HY-P0281). INF7TAT can associate with other macromolecules through non-covalent associations. INF7TAT can be used for non-toxic delivery of siRNAs .
    INF7TAT
  • HY-P5307A
    Peptide A5K acetate

    INF7-A5K-TAT acetate

    		 Biochemical Assay Reagents Others
    Peptide A5K (INF7-A5K-TAT) acetate is an amphiphilic peptide derived from the HA2-TAT fusion scaffold. Peptide A5K acetate can non-covalently bind to CRISPR ribonucleoproteins and efficiently deliver them to cells, such as primary human T cells, B cells, and NK cells. Peptide A5K acetate enables low-toxicity, precise, and multiplex genome editing, holding great application potential in the field of cell therapy .
    Peptide A5K acetate
  • HY-103177
    PSB-10 hydrochloride

    		Adenosine Receptor Inflammation/Immunology
    PSB-10 hydrochloride is a potent and selective antagonist of human adenosine A3 receptor (A3AR), with a Ki of 0.44 nM. PSB-10 hydrochloride shows more than 800-fold selectivity for hA3 over rA1, rA2A, hA1, hA2A and hA2B receptors (Ki=805, 6040, 1700, 2700, 30000 nM, respectively). PSB-10 hydrochloride produces thermal hyperalgesia in mice [2].
    PSB-10 hydrochloride
  • HY-163701
    hA2AAR antagonist 1

    		Adenosine Receptor Cancer
    hA2AAR antagonist 1 (compound 4a) is a highly selective hA2AAR antagonist with a Ki of 5 nM. hA2AAR antagonist 1 can be used in the study of immune-oncology .
    hA2AAR antagonist 1
  • HY-146979
    hA2A/hCA XII modulator 1

    		Adenosine Receptor Carbonic Anhydrase Cancer
    hA2A/hCA XII modulator 1 (compound 14), a triazolopirazine, is a potent hA2A adenosine receptor (hA2AAR) antagonist with Kis of 6.4 nM, 4.819 μM, >30 μM for hA2AAR, hA1AR, hA3AR, respectively. hA2A/hCA XII modulator 1 is a potent human carbonic anhydrase XII (hCA XII) inhibitor with Kis of 6.2 nM, 46 nM, 466 nM, 8.351 μM for hCA XII, hCA II, hCA IX and hCA I, respectively. hA2A/hCA XII modulator 1 has the potential for cancer research .
    hA2A/hCA XII modulator 1
  • HY-RS09943
    P4HA2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    P4HA2 Human Pre-designed siRNA Set A contains three designed siRNAs for P4HA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    P4HA2 Human Pre-designed siRNA Set A
    P4HA2 Human Pre-designed siRNA Set A
  • HY-RS25160
    P4ha2 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    P4ha2 Rat Pre-designed siRNA Set A contains three designed siRNAs for P4ha2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    P4ha2 Rat Pre-designed siRNA Set A
    P4ha2 Rat Pre-designed siRNA Set A
  • HY-RS08943
    MYO1G Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    MYO1G Human Pre-designed siRNA Set A contains three designed siRNAs for MYO1G gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MYO1G Human Pre-designed siRNA Set A
    MYO1G Human Pre-designed siRNA Set A
  • HY-149647
    HD-2a

    		JAK STAT Inflammation/Immunology
    HA-2a can inhibit the JAK2/STAT3 pathway via downregulates circDcbld2 expression in RAW264.7 cells .
    HD-2a
  • HY-175487
    A2AAR antagonist 4

    		Adenosine Receptor Cancer
    A2AAR antagonist 4 is an orally active A2A Adenosine receptor antagonist with a Ki of 0.36 nM and a KB of 1 nM at hA2AAR. A2AAR antagonist 4 fully inhibits hA2AAR and hA2bAR at 10 μM. A2AAR antagonist 4 can be used for research of cancer, such as MC38 tiumor .
    A2AAR antagonist 4
  • HY-144116
    A1AR antagonist 2

    		Adenosine Receptor Neurological Disease
    A1AR antagonist 2 (compound 18h) is a potent A1 adenosine receptor (AR) antagonist with Kis of 1.49, 10.2, and 50.1 nM for hA1, hA2A and hA2B, respectively .
    A1AR antagonist 2
  • HY-144115
    A1AR antagonist 1

    		Adenosine Receptor Neurological Disease
    A1AR antagonist 1 (compound 18g) is a potent A1 adenosine receptor (AR) antagonist with Kis of 2.08, 6.91, and 31.2 nM for hA1, hA2A and hA2B, respectively .
    A1AR antagonist 1
  • HY-175851
    A2AAR antagonist 5

    		Adenosine Receptor Neurological Disease
    A2AAR antagonist 5 is a selective A2AAR antagonist. A2AAR antagonist 5 inhibits NECA-stimulated adenylyl cyclase activity in hA2AAR-expressing CHO cells with an IC50 value of 1863 nM. A2AAR antagonist 5 possesses strong free radical scavenging activity, with an EC50 value of 22.21 μM in the DPPH assay. A2AAR antagonist 5 exerts notable neuroprotective effects in in vitro cerebral ischemia models. A2AAR antagonist 5 can be used for the study of cerebral ischemia .
    A2AAR antagonist 5
  • HY-147541
    A2A/A3 AR antagonist-1

    		Adenosine Receptor Inflammation/Immunology
    A2A/A3 AR antagonist-1 (compound 23) is a dual A2A/A3 adenosine receptor (AR) fluorescent ligand, with Kis of 90 nM and 31.8 nM for hA2A AR and hA3 AR, respectively .
    A2A/A3 AR antagonist-1
  • HY-110186
    PQ-69

    		Adenosine Receptor Metabolic Disease
    PQ-69 is a potent and selective adenosine A1 receptor antagonist with inverse agonist activity. PQ-69 binds to hA1 receptor with a Ki value of 0.96 nM, is 217-fold more selective compared with hA2A receptors (Ki=208 nM) and >1,000-fold selectivity over hA3 receptor (Ki >100 μM). PQ-69 can be used for the research of renal dysfunction .
    PQ-69
  • HY-115862
    Benzo[c][1,8]naphthyridin-6(5H)-one

    		Adenosine Receptor PARP Aurora Kinase Cardiovascular Disease Cancer
    Benzo[c][1,8]naphthyridin-6(5H)-one exhibits low micromolar affinity to human adenosine receptor (AR) A1 and hA2A, with Ki of 4.6 and 4.8 μM. Benzo[c][1,8]naphthyridin-6(5H)-one is inhibitor for poly ADP-ribose polymerase-1 (PARP-1) and aurora kinase A, with IC50 of 0.311 and 5.5 μM [2] .
    Benzo[c][1,8]naphthyridin-6(5H)-one
  • HY-170525
    CD73-IN-19

    		CD73 Inflammation/Immunology
    CD73-IN-19 (Compound 4ab) is a CD73 inhibitor (with a 44% inhibition rate of CD73 enzymatic activity at 100 μM). CD73-IN-19 (at 10 μM and 100 μM) can completely antagonize the blockade of T cell proliferation induced by TCR (T cell receptor) triggering (which is induced by CD73 activity), and it can also inhibit the hA2A receptor activity in HEK-293 cells (Ki is 3.31 μM). CD73-IN-19 holds promise for research in the field of immune diseases .
    CD73-IN-19
  • HY-RS18674
    P4ha2 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    P4ha2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for P4ha2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    P4ha2 Mouse Pre-designed siRNA Set A
    P4ha2 Mouse Pre-designed siRNA Set A
  • HY-179605
    AR ligand-49

    		Androgen Receptor Others
    AR ligand-49 (Compound 4q) is a dual ligand for the adenosine A2A receptor (A2AAR) and the A3 receptor (A3AR). Its Ki values are 15 and 4.5 nM respectively. AR ligand-49 exhibits reverse agonistic activity at hA2AAR and antagonistic activity at hA3AR. AR ligand-49 can be used for the study of the design and development of adenosine receptor ligands .
    AR ligand-49
  • HY-179681
    A2A/A3 agonist-1

    		Adenosine Receptor Inflammation/Immunology
    A2A/A3 agonist-1 is a dual A2A/A3 adenosine receptor agonist. A2A/A3 agonist-1 has a Ki value of 2.9 nM and an EC50 of 0.51 nM for hA2AAR. A2A/A3 agonist-1 has a Ki of 0.8 nM and an EC50 < 0.10 nM for hA3AR. A2A/A3 agonist-1 possesses anti-inflammatory activity and can be used for the research of inflammatory diseases .
    A2A/A3 agonist-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: